TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Secondary Prevention of Small Subcortical Strokes (SPS3) Trial
Brief Summary: The goal of this study is to learn if combination antiplatelet therapy (aspirin and clopidogrel) is more effective than aspirin alone for the prevention of recurrent stroke and cognitive decline, and if intensive blood pressure control is associated with fewer recurrent strokes and cognitive decline.

On July 21, 2011 the DSMB recommended terminating the anti platelet arm of the study due to an imbalance of overall and major non-CNS hemorrhagic SAE's and total deaths in the investigational anti platelet combination of aspirin + clopidogrel and an interim statistical analysis that demonstrated futility in the investigational anti platelet arm. It was recommended that patients be continued on standard care of aspirin mono therapy until their study close-out visit. Also, recommended the continuation and completion of the plood pressure arm following the protocol.


Options:
A: Arm Label: Antiplatelet; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin, Drug: clopidogrel, Other: placebo | Arm Label: Blood pressure; Type: ACTIVE_COMPARATOR; Interventions: Other: Target of Blood Pressure | Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): Antiplatelet | Intervention Type: DRUG; Name: clopidogrel; Assigned to Arm(s): Antiplatelet | Intervention Type: OTHER; Name: Target of Blood Pressure; Assigned to Arm(s): Blood pressure | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Antiplatelet
B: Arm Label: Intensive pharmacist case management; Type: EXPERIMENTAL; Interventions: Drug: Antihypertensive agents and lipid lowering therapy | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: DRUG; Name: Antihypertensive agents and lipid lowering therapy; Assigned to Arm(s): Intensive pharmacist case management | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual care
C: Arm Label: Arm 1 Secondary Risk Factor Management; Type: EXPERIMENTAL; Interventions: Behavioral: Physician stroke guideline adherence, Behavioral: Stroke Self Management | Arm Label: Attention Control Group; Type: PLACEBO_COMPARATOR; Interventions: Other: Attention Control Group | Intervention Type: BEHAVIORAL; Name: Physician stroke guideline adherence; Assigned to Arm(s): Arm 1 Secondary Risk Factor Management | Intervention Type: BEHAVIORAL; Name: Stroke Self Management; Assigned to Arm(s): Arm 1 Secondary Risk Factor Management | Intervention Type: OTHER; Name: Attention Control Group; Assigned to Arm(s): Attention Control Group
D: Arm Label: Behavioral; Type: EXPERIMENTAL; Interventions: Behavioral: Smart-phone based technology | Arm Label: Usual background care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Smart-phone based technology; Assigned to Arm(s): Behavioral

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Secondary Prevention of Small Subcortical Strokes (SPS3) Trial
Brief Summary: The goal of this study is to learn if combination antiplatelet therapy (aspirin and clopidogrel) is more effective than aspirin alone for the prevention of recurrent stroke and cognitive decline, and if intensive blood pressure control is associated with fewer recurrent strokes and cognitive decline.

On July 21, 2011 the DSMB recommended terminating the anti platelet arm of the study due to an imbalance of overall and major non-CNS hemorrhagic SAE's and total deaths in the investigational anti platelet combination of aspirin + clopidogrel and an interim statistical analysis that demonstrated futility in the investigational anti platelet arm. It was recommended that patients be continued on standard care of aspirin mono therapy until their study close-out visit. Also, recommended the continuation and completion of the plood pressure arm following the protocol.


Options:
A: Arm Label: Antiplatelet; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin, Drug: clopidogrel, Other: placebo | Arm Label: Blood pressure; Type: ACTIVE_COMPARATOR; Interventions: Other: Target of Blood Pressure | Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): Antiplatelet | Intervention Type: DRUG; Name: clopidogrel; Assigned to Arm(s): Antiplatelet | Intervention Type: OTHER; Name: Target of Blood Pressure; Assigned to Arm(s): Blood pressure | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Antiplatelet
B: Arm Label: intensive medical management plus stenting; Type: EXPERIMENTAL; Interventions: Device: intracranial angioplasty and stenting | Arm Label: intensive medical management alone; Type: EXPERIMENTAL; Interventions: Other: intensive medical management | Intervention Type: DEVICE; Name: intracranial angioplasty and stenting; Assigned to Arm(s): intensive medical management plus stenting | Intervention Type: OTHER; Name: intensive medical management; Assigned to Arm(s): intensive medical management alone
C: Arm Label: Wingspan Stent System; Type: OTHER; Interventions: Device: Wingspan Stent System | Intervention Type: DEVICE; Name: Wingspan Stent System; Assigned to Arm(s): Wingspan Stent System
D: Arm Label: aggressive medical treatment; Type: N/A; Interventions: Device: intravascular stent therapy | Intervention Type: DEVICE; Name: intravascular stent therapy; Assigned to Arm(s): aggressive medical treatment

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Secondary Prevention of Small Subcortical Strokes (SPS3) Trial
Brief Summary: The goal of this study is to learn if combination antiplatelet therapy (aspirin and clopidogrel) is more effective than aspirin alone for the prevention of recurrent stroke and cognitive decline, and if intensive blood pressure control is associated with fewer recurrent strokes and cognitive decline.

On July 21, 2011 the DSMB recommended terminating the anti platelet arm of the study due to an imbalance of overall and major non-CNS hemorrhagic SAE's and total deaths in the investigational anti platelet combination of aspirin + clopidogrel and an interim statistical analysis that demonstrated futility in the investigational anti platelet arm. It was recommended that patients be continued on standard care of aspirin mono therapy until their study close-out visit. Also, recommended the continuation and completion of the plood pressure arm following the protocol.


Options:
A: Arm Label: Antiplatelet; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin, Drug: clopidogrel, Other: placebo | Arm Label: Blood pressure; Type: ACTIVE_COMPARATOR; Interventions: Other: Target of Blood Pressure | Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): Antiplatelet | Intervention Type: DRUG; Name: clopidogrel; Assigned to Arm(s): Antiplatelet | Intervention Type: OTHER; Name: Target of Blood Pressure; Assigned to Arm(s): Blood pressure | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Antiplatelet
B: Arm Label: Combination Clopidogrel and asprin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: Asprin and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of clopidogrel and Asprin | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Combination Clopidogrel and asprin | Intervention Type: DRUG; Name: Placebo of clopidogrel and Asprin; Assigned to Arm(s): Asprin and placebo
C: Arm Label: ticagrelor; Type: EXPERIMENTAL; Interventions: Drug: ticagrelor | Arm Label: Acetylsalicylic acid (ASA); Type: ACTIVE_COMPARATOR; Interventions: Drug: Acetylsalicylic acid (ASA) | Intervention Type: DRUG; Name: ticagrelor; Assigned to Arm(s): ticagrelor | Intervention Type: DRUG; Name: Acetylsalicylic acid (ASA); Assigned to Arm(s): Acetylsalicylic acid (ASA)
D: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Secondary Prevention of Small Subcortical Strokes (SPS3) Trial
Brief Summary: The goal of this study is to learn if combination antiplatelet therapy (aspirin and clopidogrel) is more effective than aspirin alone for the prevention of recurrent stroke and cognitive decline, and if intensive blood pressure control is associated with fewer recurrent strokes and cognitive decline.

On July 21, 2011 the DSMB recommended terminating the anti platelet arm of the study due to an imbalance of overall and major non-CNS hemorrhagic SAE's and total deaths in the investigational anti platelet combination of aspirin + clopidogrel and an interim statistical analysis that demonstrated futility in the investigational anti platelet arm. It was recommended that patients be continued on standard care of aspirin mono therapy until their study close-out visit. Also, recommended the continuation and completion of the plood pressure arm following the protocol.


Options:
A: Arm Label: Wingspan Stent System; Type: OTHER; Interventions: Device: Wingspan Stent System | Intervention Type: DEVICE; Name: Wingspan Stent System; Assigned to Arm(s): Wingspan Stent System
B: Arm Label: Carotid Artery Endarterectomy (CEA); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Carotid Endarterectomy (CEA) | Arm Label: Carotid Artery Stenting (CAS); Type: ACTIVE_COMPARATOR; Interventions: Device: Carotid Artery Stenting (CAS) | Intervention Type: PROCEDURE; Name: Carotid Endarterectomy (CEA); Assigned to Arm(s): Carotid Artery Endarterectomy (CEA) | Intervention Type: DEVICE; Name: Carotid Artery Stenting (CAS); Assigned to Arm(s): Carotid Artery Stenting (CAS)
C: Arm Label: Antiplatelet; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin, Drug: clopidogrel, Other: placebo | Arm Label: Blood pressure; Type: ACTIVE_COMPARATOR; Interventions: Other: Target of Blood Pressure | Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): Antiplatelet | Intervention Type: DRUG; Name: clopidogrel; Assigned to Arm(s): Antiplatelet | Intervention Type: OTHER; Name: Target of Blood Pressure; Assigned to Arm(s): Blood pressure | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Antiplatelet
D: Arm Label: Stent Group; Type: EXPERIMENTAL; Interventions: Device: Pharos Vitesse Neurovascular Stent System (Stent implantation) + Medical therapy (Aspirin and Clopidogrel) | Arm Label: Medical Therapy Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin and Clopidogrel (Medical therapy) | Intervention Type: DEVICE; Name: Pharos Vitesse Neurovascular Stent System (Stent implantation) + Medical therapy (Aspirin and Clopidogrel); Assigned to Arm(s): Stent Group | Intervention Type: DRUG; Name: Aspirin and Clopidogrel (Medical therapy); Assigned to Arm(s): Medical Therapy Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Secondary Prevention of Small Subcortical Strokes (SPS3) Trial
Brief Summary: The goal of this study is to learn if combination antiplatelet therapy (aspirin and clopidogrel) is more effective than aspirin alone for the prevention of recurrent stroke and cognitive decline, and if intensive blood pressure control is associated with fewer recurrent strokes and cognitive decline.

On July 21, 2011 the DSMB recommended terminating the anti platelet arm of the study due to an imbalance of overall and major non-CNS hemorrhagic SAE's and total deaths in the investigational anti platelet combination of aspirin + clopidogrel and an interim statistical analysis that demonstrated futility in the investigational anti platelet arm. It was recommended that patients be continued on standard care of aspirin mono therapy until their study close-out visit. Also, recommended the continuation and completion of the plood pressure arm following the protocol.


Options:
A: Arm Label: Aggressive BP lowering; Type: EXPERIMENTAL; Interventions: Procedure: Aggressive BP lowering | Arm Label: Modest BP lowering; Type: ACTIVE_COMPARATOR; Interventions: Procedure: modest blood pressure lowering | Intervention Type: PROCEDURE; Name: Aggressive BP lowering; Assigned to Arm(s): Aggressive BP lowering | Intervention Type: PROCEDURE; Name: modest blood pressure lowering; Assigned to Arm(s): Modest BP lowering
B: Arm Label: Intensive Control of Systolic Blood Pressure (SBP); Type: EXPERIMENTAL; Interventions: Drug: Intensive Control of Systolic Blood Pressure (SBP) | Arm Label: Standard Control of Systolic Blood Pressure; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard control of Systolic Blood Pressure (SBP) | Intervention Type: DRUG; Name: Intensive Control of Systolic Blood Pressure (SBP); Assigned to Arm(s): Intensive Control of Systolic Blood Pressure (SBP) | Intervention Type: DRUG; Name: Standard control of Systolic Blood Pressure (SBP); Assigned to Arm(s): Standard Control of Systolic Blood Pressure
C: Arm Label: Antiplatelet; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin, Drug: clopidogrel, Other: placebo | Arm Label: Blood pressure; Type: ACTIVE_COMPARATOR; Interventions: Other: Target of Blood Pressure | Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): Antiplatelet | Intervention Type: DRUG; Name: clopidogrel; Assigned to Arm(s): Antiplatelet | Intervention Type: OTHER; Name: Target of Blood Pressure; Assigned to Arm(s): Blood pressure | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Antiplatelet
D: Arm Label: Intensive; Type: EXPERIMENTAL; Interventions: Other: Anti-hypertensive therapy to SBP 130 mm Hg | Arm Label: Standard; Type: ACTIVE_COMPARATOR; Interventions: Other: Anti-hypertensive therapy to SBP 145 mm Hg | Intervention Type: OTHER; Name: Anti-hypertensive therapy to SBP 130 mm Hg; Assigned to Arm(s): Intensive | Intervention Type: OTHER; Name: Anti-hypertensive therapy to SBP 145 mm Hg; Assigned to Arm(s): Standard

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Secondary Prevention of Small Subcortical Strokes (SPS3) Trial
Brief Summary: The goal of this study is to learn if combination antiplatelet therapy (aspirin and clopidogrel) is more effective than aspirin alone for the prevention of recurrent stroke and cognitive decline, and if intensive blood pressure control is associated with fewer recurrent strokes and cognitive decline.

On July 21, 2011 the DSMB recommended terminating the anti platelet arm of the study due to an imbalance of overall and major non-CNS hemorrhagic SAE's and total deaths in the investigational anti platelet combination of aspirin + clopidogrel and an interim statistical analysis that demonstrated futility in the investigational anti platelet arm. It was recommended that patients be continued on standard care of aspirin mono therapy until their study close-out visit. Also, recommended the continuation and completion of the plood pressure arm following the protocol.


Options:
A: Arm Label: Antiplatelet; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin, Drug: clopidogrel, Other: placebo | Arm Label: Blood pressure; Type: ACTIVE_COMPARATOR; Interventions: Other: Target of Blood Pressure | Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): Antiplatelet | Intervention Type: DRUG; Name: clopidogrel; Assigned to Arm(s): Antiplatelet | Intervention Type: OTHER; Name: Target of Blood Pressure; Assigned to Arm(s): Blood pressure | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Antiplatelet
B: Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): N/A
C: Arm Label: Aspirin + clopidogrel + oral anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Device: PCI (percutaneous coronary intervention) | Arm Label: Oral anticoagulants + clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Device: PCI (percutaneous coronary intervention) | Intervention Type: DEVICE; Name: PCI (percutaneous coronary intervention); Assigned to Arm(s): Aspirin + clopidogrel + oral anticoagulation, Oral anticoagulants + clopidogrel
D: Intervention Type: DRUG; Name: anticoagulation; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: aspirin and dipyridamole; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: aspirin alone; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial of Male Circumcision to Reduce HIV Incidence
Brief Summary: The Luo tribe of Kisumu, Kenya, does not traditionally practice male circumcision (MC). This study will work with the Luo tribe to test the effectiveness of MC on reducing the risk of HIV infections in young men.


Options:
A: Intervention Type: PROCEDURE; Name: Male Circumcision; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Stepping Stones | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: stepping Stones short | Intervention Type: BEHAVIORAL; Name: Stepping Stones; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: stepping Stones short; Assigned to Arm(s): 2
C: Arm Label: Circumcised immediately; Type: ACTIVE_COMPARATOR; Interventions: Procedure: male circumcision | Arm Label: Delayed Circumcision; Type: PLACEBO_COMPARATOR; Interventions: Procedure: male circumcision | Intervention Type: PROCEDURE; Name: male circumcision; Assigned to Arm(s): Circumcised immediately, Delayed Circumcision
D: Arm Label: Vaccine; Type: ACTIVE_COMPARATOR; Interventions: Biological: ALVAC-HIV vCP1521 + AIDSVAX | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: ALVAC Placebo + AIDSVAX Placebo | Intervention Type: BIOLOGICAL; Name: ALVAC-HIV vCP1521 + AIDSVAX; Assigned to Arm(s): Vaccine | Intervention Type: OTHER; Name: ALVAC Placebo + AIDSVAX Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial of Male Circumcision to Reduce HIV Incidence
Brief Summary: The Luo tribe of Kisumu, Kenya, does not traditionally practice male circumcision (MC). This study will work with the Luo tribe to test the effectiveness of MC on reducing the risk of HIV infections in young men.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Shang Ring | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Male circumcision | Intervention Type: DEVICE; Name: Shang Ring; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Male circumcision; Assigned to Arm(s): 2
B: Arm Label: PrePex™; Type: EXPERIMENTAL; Interventions: Device: PrePex™ device for adult male circumcision | Arm Label: Surgical; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgical circumcision | Intervention Type: DEVICE; Name: PrePex™ device for adult male circumcision; Assigned to Arm(s): PrePex™ | Intervention Type: PROCEDURE; Name: Surgical circumcision; Assigned to Arm(s): Surgical
C: Arm Label: Circumcised immediately; Type: ACTIVE_COMPARATOR; Interventions: Procedure: male circumcision | Arm Label: Delayed Circumcision; Type: PLACEBO_COMPARATOR; Interventions: Procedure: male circumcision | Intervention Type: PROCEDURE; Name: male circumcision; Assigned to Arm(s): Circumcised immediately, Delayed Circumcision
D: Intervention Type: PROCEDURE; Name: Adult male circumcision; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Increased Access to Emergency Contraceptive Pills
Brief Summary: This study will evaluate the effect of easy access to emergency contraceptive pills (ECPs) on the rates of pregnancy and sexually transmitted infections (STIs).


Options:
A: Intervention Type: BEHAVIORAL; Name: Increased access to emergency contraceptive pills; Assigned to Arm(s): N/A
B: Arm Label: Counseling for LAM; Type: ACTIVE_COMPARATOR; Interventions: Drug: Counseling for LAM+ LNG-EC | Arm Label: Counseling for LAM+ LNG-EC; Type: EXPERIMENTAL; Interventions: Drug: Counseling for LAM+ LNG-EC | Intervention Type: DRUG; Name: Counseling for LAM+ LNG-EC; Assigned to Arm(s): Counseling for LAM, Counseling for LAM+ LNG-EC
C: Intervention Type: DRUG; Name: CDB-2914; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: levonorgestrel; Assigned to Arm(s): N/A
D: Arm Label: Copper IUD; Type: N/A; Interventions: Drug: Copper IUD | Arm Label: Levonorgestrel IUD; Type: N/A; Interventions: Drug: Levonorgestrel IUD | Intervention Type: DRUG; Name: Copper IUD; Assigned to Arm(s): Copper IUD | Intervention Type: DRUG; Name: Levonorgestrel IUD; Assigned to Arm(s): Levonorgestrel IUD

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Increased Access to Emergency Contraceptive Pills
Brief Summary: This study will evaluate the effect of easy access to emergency contraceptive pills (ECPs) on the rates of pregnancy and sexually transmitted infections (STIs).


Options:
A: Intervention Type: DEVICE; Name: Ortho All-Flex diaphragm and Replens lubricant gel; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Health Improvement Project for Teens on HIV Prevention | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Health Improvement Project for Teens on HIV Prevention | Intervention Type: BEHAVIORAL; Name: Health Improvement Project for Teens on HIV Prevention; Assigned to Arm(s): 1, 2
C: Intervention Type: BEHAVIORAL; Name: Increased access to emergency contraceptive pills; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Families Talking Together | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active control on hygiene and nutrition | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Active control on hygiene and nutrition; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Families Talking Together; Assigned to Arm(s): 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Increased Access to Emergency Contraceptive Pills
Brief Summary: This study will evaluate the effect of easy access to emergency contraceptive pills (ECPs) on the rates of pregnancy and sexually transmitted infections (STIs).


Options:
A: Intervention Type: BEHAVIORAL; Name: Increased access to emergency contraceptive pills; Assigned to Arm(s): N/A
B: Arm Label: Copper IUD; Type: N/A; Interventions: Drug: Copper IUD | Arm Label: Levonorgestrel IUD; Type: N/A; Interventions: Drug: Levonorgestrel IUD | Intervention Type: DRUG; Name: Copper IUD; Assigned to Arm(s): Copper IUD | Intervention Type: DRUG; Name: Levonorgestrel IUD; Assigned to Arm(s): Levonorgestrel IUD
C: Arm Label: Counseling for LAM; Type: ACTIVE_COMPARATOR; Interventions: Drug: Counseling for LAM+ LNG-EC | Arm Label: Counseling for LAM+ LNG-EC; Type: EXPERIMENTAL; Interventions: Drug: Counseling for LAM+ LNG-EC | Intervention Type: DRUG; Name: Counseling for LAM+ LNG-EC; Assigned to Arm(s): Counseling for LAM, Counseling for LAM+ LNG-EC
D: Intervention Type: DRUG; Name: CDB-2914; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: levonorgestrel; Assigned to Arm(s): N/A

Answer: A